Oral contraceptives and risk of thrombosis: Is laboratory screening for thrombophilia efficient?;Thromboserisiko bei oralen Kontrazeptiva: Stellenwert eines Thrombophilie-Screenings

Vasa - Journal of Vascular Diseases

Volumn 25, Issue 3, 1996, Pages 209-220

  Bauersachs, R ^a   Kuhl, H ^a   Lindhoff Last, E ^a   Ehrly, A M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DESOGESTREL; GESTODENE;

ANTITHROMBIN III DEFICIENCY; COST BENEFIT ANALYSIS; DISEASE PREDISPOSITION; HIGH RISK POPULATION; HUMAN; ORAL CONTRACEPTION; OVULATION INHIBITION; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; RISK MANAGEMENT; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; BLOOD COAGULATION TESTS; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, ORAL, SYNTHETIC; COST-BENEFIT ANALYSIS; DESOGESTREL; FEMALE; HUMANS; MASS SCREENING; NORPREGNENES; PREGNANCY; RISK FACTORS; THROMBOSIS;

EID: 0029787278     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. ALLAART CF, POORT SR, ROSENDAAL FR, REITSMA PH, BERTINA RM, BRIET E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
2. ALVING BM, COMP PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992; 167: 1184-91.
3. Arzneimittelkommission der deutschen Ärzteschaft. Gestoden und Desogestrel-haltige Arzneimittel. Dt. Ärztebl 1996; 93: 46-7.
4. ASHERSON RA, HARRIS NE, HUGHES GRV. Complications of oral contraceptives and antiphospholipid antibodies: reply to the letter by Bruneau et al. Arthritis Rheum 1987; 30: 575-6.
5. BARNES RW, KRAFT T, HOAK JC. Erroneous clinical diagnosis of leg vein thrombosis in women on oral contraceptives. Obstet Gynecol 1978; 51: 556-8.
6. BEN TAL O, ZIVELIN A, SELIGSOHN U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-4.
7. BERTINA RM, KOELEMAN BP, KOSTER T, ROSENDAAL FR, DIRVEN RJ, DE RONDE H, VAN DER VELDEN PA, REITSMA PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
8. BLOEMENKAMP KWM, ROSENDAAL FR, HELMERHORST FM, BÜLLER HR, VANDENBROUCKE JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
9. BÖTTIGER LE, WESTERHOLM B. Oral contraceptives and thromboembolic disease. Swedish experience. Acta med scand 1971; 190: 455-63.
10. BRIET E, VAN DER MEER FJ, ROSENDAAL FR, HOUWING DUISTERMAAT JJ, VAN HOUWELINGEN HC. The family history and inherited thrombophilia. Br J Haematol 1994; 87: 348-52.
11. BROEKMANS AW. Hereditary protein C deficiency. Haemostasis 1985; 15: 233-40.
12. CONARD J, HORELLOU MH, VAN DREDEN P, LECOMPTE T, SAMAMA M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb-Haemost 1990; 63: 319-20.
13. COON WW, WILLIS PW, KELLER JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973; 48: 839-46.
14. DAHLBÄCK B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
15. DAHLBÄCK B, CARLSSON M, SVENSSON PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
16. DEMERS C, GINSBERG JS. Deep venous thrombosis and pulmonary embolism in pregnancy. Clin Chest Med 1992; 13: 645-56.
17. ENGESSER L. Thrombophilia - Disorders of blood coagulation and fibrinolysis. Thesis: University Leiden, 1988.
18. ENGESSER L, BROEKMANS AW, BRIET E, BROMMER EJ, BERTINA RM. Hereditary protein S deficiency: clinical manifestations. Ann-Intern-Med 1987; 106: 677-82.
19. GERSTMAN BB, PIPER JM, FREIMAN JP, TOMITA DK, KENNEDY DL, FERGUSON WJ, BENNETT RC. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1990; 19: 931-6.
20. GERSTMAN BB, PIPER JM, TOMITA DK, FERGUSON WJ, STADEL BV, LUNDIN FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
21. GINSBURG KS, LIANG MH, NEWCOMER L, GOLDHABER SZ, SCHUR PH, HENNEKENS CH, STAMPFER MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002.
22. GLADSON CL, SCHARRER I, HACH V, BECK KH, GRIFFIN JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
23. GRIFFIN HJ, EVATT B, ZIMMERMAN TS, KLEISS AJ, WIDEMAN C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
24. HEIJBOER H, BRANDJES DP, BULLER HR, STURK A, TEN CATE JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-6.
25. HELLGREN M, TENGBORN L, ABILDGAARD U. Pregnancy in women with congenital Antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-41.
26. HELLGREN M, SVENSSON PJ, DAHLBÄCK B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
27. HELMRICH SP, ROSENBERG L, KAUFMAN DW, STROM B, SHAPIRO S. Venous thromboembolism in relation to oral contraceptive use. Obstet-Gynecol 1987; 69: 91-5.
28. HIRSH J, PIOVELLA F, PINI M. Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med 1989; 87: 34S-38S.
29. JICK H, JICK SS, GUREWICH V, MYERES MW, VASILAKIS C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
30. KAY CR. The Royal College of General Practitioners' Oral Contraception Study: some recent observations. Clin Obstet Gynaecol 1984; 11: 759-86.
31. KIERKEGAARD A. Incidence of acute deep vein thrombosis in two districts. Acta Chir Scand 1980; 146: 267-9.
32. KOELEMAN BP, REITSMA PH, ALLAART CF, BERTINA RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
33. KOSTER T, ROSENDAAL FR, DE RONDE H, BRIET E, VANDENBROUCKE JP, BERTINA RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
34. KOSTER T, ROSENDAAL FR, BRIET E, VAN DER MEER FJ, COLLY LP, TRIENEKENS PH, POORT SR, REITSMA PH, VANDENBROUCKE JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
35. KOSTER T, SMALL RA, ROSENDAAL FR, HELMERHORST FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31-7.
36. LETZKY EA, DE SWIET M. Thromboembolism in pregnancy and initial management. Br J Haematol 1984; 57: 542-52.
37. LEWIS MA, SPITZER WO, HEINEMANN LAJ, MACRAE KD, BRUPPACHER R, THOROGOOD M, on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90.
38. MALM J, LAURELL M, NILSSON IM, DAHLBÄCK B. Thromboembolic disease - Critical Evaluation of laboratory investigation. Thromb Haemostas 1992; 68: 7-13.
39. MEADE TW, HAINES AP, NORTH WR et al. Hemostatic, lipid and blood-pressure profiles of women on oral contraception containing 50 microgram or 30 microgram estrogen. Lancet 1977; ii: 948-52.
40. MILETICH J, SHERMAN L, BROZE G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-6.
41. MILETICH JP, PRESCOTT SM, WHITE R, MAJERUS PW, BOVILL EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
42. NYLANDER G, OLIVECRONA H. The phlebographic pattern of acute leg thrombosis within a defined urban population. Acta Chir Scand 1976; 142: 505-11.
43. ODEGARD OR, ABILDGAARD U. Antithrombin III: critical review of assay methods. Haemostasis 1978; 7: 127-32.
44. PABINGER I, SCHNEIDER B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-52.
45. PABINGER I, KYRLE PA, HEISTINGER M, EICHINGER S, WITTMANN E, LECHNER K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994; 71: 441-5.
46. ROSENBERG RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
47. ROSENBERG RD, BAUER KA. Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. Hum-Pathol 1987; 18: 253-62.
48. ROSENDAAL FR, BERTINA RM, REITSMA PH. DNA analysis of APC resistance. Lancet 1994; 343: 1289-90.
49. ROSENDAAL FR, KOSTER T, VANDENBROUCKE JP, REITSMA PH. High risk of thrombosis in patients homozygous for factor V Leiden (Activated Protein C Resistance). Blood 1995; 85: 1504-8.
50. SHI W, KRILIS SA, CHONG BH, GORDON S, CHESTERMAN CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust-N-Z-J-Med 1990; 20: 231-6.
51. SIPES SL, WEINER CP. Venous thromboembolic disease in pregnancy. Semin-Perinatol 1990; 14: 103-8.
52. SPITZER WO, LEWIS MA, HEINEMANN LAJ, THOROGOOD M, MACRAE KD, on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8.
53. STADEL BV. Oral contraceptives and cardiovascular disease (First of two parts). N Engl J Med 1981; 305: 612-8.
54. STADEL BV. Oral contraceptives and cardiovascular disease (Second of two parts). N Engl J Med 1981; 305: 672-7.
55. SVENSSON PJ, DAHLBÄCK B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
56. TABERNERO MD, TOMAS JF, ALBERCA I, ORFAO A, LOPEZ BORRASCA A, VICENTE V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-54.
57. TAIT RC, WALKER ID, ISLAM SI, MCCALL F, CONKIE JA, MITCHELL R, DAVIDSON JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-80.
58. TAUBERT HD, KUHL H. Kontrazeption mit Hormonen. Suttgart: Thieme, 1955: 296-319.
59. THALER E, LECHNER K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-74.
60. TUDDENHAM EG. Thrombophilia: the new factor is old factor V. Lancet 1994; 343: 1515-6.
61. VANDENBROUCKE JP, KOSTER T, BRIET E, REITSMA PH, BERTINA RM, ROSENDAAL FR. Increased risk of venous thrombosis in oral-anticontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
62. VESSEY M, MANT D, SMITH A, YEATES D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Brit Med J 1986; 292: 526.
63. VIKYDAL R, KORNINGER C, KYRLE PA, NIESSNER H, PABINGER I, THALER E, LECHNER K. The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54: 744-5.
64. VILA P, HERNANDEZ MC, LOPEZ FERNANDEZ MF, BATLLE J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-13.
65. WEENIK GH, TREFFERS PE, KAHLE LH, TEN CATE JW. Antithrombin III in normal pregnancy. Thrombosis Research 1982; 26: 281-7.
66. WEISS N. Third-generation oral contraceptives: how risky? Lancet 1995; 346: 1570.
67. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
68. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-8.
69. ZÖLLER B, BERNTSDOTTER A, DE FRUTOS PG, DAHLBÄCK B. Resistance to Activated Protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.